KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience | Cancer Genomics & Proteomics
KRAS G12V Protein, Human, Recombinant, Biotinylated – Amid Biosciences | Protein Engineering Company
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer | Nature Reviews Gastroenterology & Hepatology
Acquired Resistance to KRASG12C Inhibition in Cancer | NEJM
Figure 2 from KRAS: feeding pancreatic cancer proliferation. | Semantic Scholar
The current understanding of KRAS protein structure and dynamics | Semantic Scholar
Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors | Anticancer Research
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials | European Respiratory Society
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
The KRAS-G12C inhibitor: activity and resistance | Cancer Gene Therapy
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge | Cell Discovery
Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine | Nature Communications
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism: Cell
Next batter up! Targeting cancers with KRAS-G12D mutations: Trends in Cancer
Cancers | Free Full-Text | Synthetic Vulnerabilities in the KRAS Pathway
Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells | PLOS ONE
Immune modulatory effects of oncogenic KRAS in cancer | Nature Communications
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
Frontiers | KRAS protein expression becomes progressively restricted during embryogenesis and in adulthood
Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling | PLOS Computational Biology
